<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYANOKIT
- hydroxocobalamin
Â injection, powder, lyophilized, for solutionÂ </strong><br>Meridian Medical Technologies, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Cyanokit safely and effectively.  See full prescribing information for Cyanokit.<br>Cyanokit<span class="Sup">Â®</span> (hydroxocobalamin for injection) 5Â g for intravenous infusion<br>Initial U.S. Approval: 1975
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Interference with Clinical Laboratory Evaluations and Clinical Methods (<a href="#s16">5.5</a>)Â Â Â Â Â Â Â Â Â Â Â Â 4/2011
 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. (<a href="#s1">1.1</a>)
 </p>
<ul class="Disc">
<li>If clinical suspicion of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is high, Cyanokit should be administered without delay. (<a href="#s2">1.2</a>)
</li>
<li>The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (<a href="#s2">1.2</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"> </p>
<ul class="Disc">
<li>The starting dose of Cyanokit for adults is 5Â g, (two 2.5Â g vials) administered by intravenous infusion over 15 minutes. (<a href="#s5">2.1</a>)
</li>
<li>Depending upon the severity of the <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and the clinical response, a second dose of 5Â g may be administered by intravenous infusion for a total dose of 10Â g. (<a href="#s5">2.1</a>)
</li>
<li>The rate of infusion for the second 5Â g dose may range from 15 minutes (for patients in extremis) to 2Â hours based on patient condition. (<a href="#s5">2.1</a>)
</li>
<li>The recommended diluent is 0.9% Sodium Chloride injection. (<a href="#s6">2.2</a>)
</li>
<li>Diluent is not included with Cyanokit. (<a href="#s6">2.2</a>)
</li>
<li>There are a number of drugs and blood products that are incompatible with Cyanokit, thus Cyanokit requires a separate intravenous line for administration. (<a href="#s7">2.3</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Cyanokit (hydroxocobalamin for injection) 5Â g for intravenous infusion consists of 2 vials, each with 2.5Â g lyophilized hydroxocobalamin dark red crystalline powder for injection. (<a href="#s9">3</a>)  After reconstitution, each vial contains hydroxocobalamin for injection, 25Â mg/mL. (<a href="#s9">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None (<a href="#s10">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Use caution in the management of patients with known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to hydroxocobalamin or cyanocobalamin. Consideration should be given to use of alternative therapies, if available. (<a href="#s13">5.2</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may include: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. (<a href="#s13">5.2</a>)
</li>
<li>Blood pressure increase: Substantial increases in blood pressure may occur following Cyanokit therapy. (<a href="#s14">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (&gt;5%) include transient <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">chromaturia</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>. (<a href="#s18">6</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS contact Meridian Medical Technologies
</span><span class="Sup">TM
</span><span class="Bold">, Inc. at 1-800-776-3637, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<ul class="Disc">
<li>Pregnancy: Based on animal studies, may cause fetal harm; however, treatment of maternal/fetal cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may be lifesaving. (<a href="#s24">8.1</a>)
</li>
<li>Nursing mothers:  Because of the unknown potential for adverse reactions in nursing infants, discontinue nursing after Cyanokit treatment. (<a href="#s26">8.3</a>)
</li>
<li>
No safety and efficacy studies have been performed in pediatric patients. (<a href="#s27">8.4</a>)</li>
</ul>
<p class="Highlighta"> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Indication
</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Identifying Patients with Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>
</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Use with Other Cyanide Antidotes
</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosing
</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation of Solution for Infusion
</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Incompatibility Information
</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Storage of Reconstituted Drug Product
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Emergency Patient Management
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Blood Pressure Increase
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use of Blood Cyanide Assay
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Interference with Clinical Laboratory Evaluations and Clinical Methods
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery
</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Pharmacology
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Smoke Inhalation Victims
</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> by Ingestion or Inhalation
</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Cross-Study Findings
</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> and <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">Chromaturia</span>
</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Pregnancy and Breastfeeding
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s0"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Indication
</h2>
<p class="First">Cyanokit is indicated for the treatment of known or suspected cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Identifying Patients with Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>
</h2>
<p class="First">Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside.
</p>
<p>The presence and extent of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>. If clinical suspicion of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is high, Cyanokit should be administered without delay.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1 Common Signs and Symptoms of Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>
</span></caption>
<col align="left" width="33.250%">
<col align="left" width="66.750%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Â Symptoms</span></td>
<td class="Rrule Toprule" align="left" valign="top"><span class="Bold">Â Signs</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</li></ul></td>
<td class="Rrule" align="left" valign="top"><ul class="Disc"><li>Altered Mental Status (e.g., <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>,<span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>)
</li></ul></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>
</li></ul></td>
<td class="Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">Coma</span>
</li></ul></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>
</li></ul></td>
<td class="Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span>
</li></ul></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">Chest tightness</span>
</li></ul></td>
<td class="Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">Tachypnea</span> / <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperpnea</span> (early)
</li></ul></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</li></ul></td>
<td class="Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4314808" conceptname="Slow respiration">Bradypnea</span> / <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> (late)
</li></ul></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> (early) / <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (late)
</li></ul></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">Cardiovascular collapse</span>
</li></ul></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</li></ul></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"><ul class="Disc"><li>Plasma lactate concentration â‰¥ 8 mmol/L
</li></ul></td>
</tr>
</tbody>
</table>
<p>In some settings, panic symptoms including <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may mimic early cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> signs. The presence of altered mental status (e.g., <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>) and/or <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> is suggestive of true cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> although these signs can occur with other toxic exposures as well.
</p>
<p>The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222.
</p>
<p><span class="Underline">Smoke Inhalation</span></p>
<p>Not all smoke inhalation victims will have cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and may present with <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, and exposure to other toxic substances making a diagnosis of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following:
</p>
<ul class="Disc">
<li>Exposure to fire or smoke in an enclosed area
</li>
<li>Presence of soot around the mouth, nose or oropharynx
</li>
<li>Altered mental status
</li>
</ul>
<p>Although <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is highly suggestive of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is a plasma lactate concentration â‰¥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> because <span class="product-label-link" type="condition" conceptid="4198996" conceptname="Carbon monoxide">carbon monoxide</span> associated with smoke inhalation also contributes to lactic <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidemia</span>). If cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is suspected, treatment should not be delayed to obtain a plasma lactate concentration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Use with Other Cyanide Antidotes
</h2>
<p class="First">Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established.  If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line.  [<span class="Italics">see Dosage and Administration (<a href="#s7">2.3</a>)</span>].
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Comprehensive treatment of acute cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> requires support of vital functions.  Cyanokit should be administered in conjunction with appropriate airway, ventilatory and circulatory support.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosing
</h2>
<p class="First">The starting dose of hydroxocobalamin for adults is 5Â g (i.e., both 2.5 g vials) administered as an intravenous infusion over 15 minutes (approximately 15Â mL/min), i.e., 7.5Â minutes/vial.  Depending upon the severity of the <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and the clinical response, a second dose of 5Â g may be administered by intravenous infusion for a total dose of 10Â g.  The rate of infusion for the second dose may range from 15 minutes (for patients in extremis) to two hours, as clinically indicated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation of Solution for Infusion
</h2>
<p class="First">Each 2.5 g vial of hydroxocobalamin for injection is to be reconstituted with 100 mL of diluent (not provided with Cyanokit) using the supplied sterile transfer spike. The recommended diluent is 0.9% Sodium Chloride injection (0.9% NaCl). Lactated Ringers injection and 5% Dextrose injection (D5W) have also been found to be compatible with hydroxocobalamin and may be used if 0.9% NaCl is not readily available. The line on each vial label represents 100 mL volume of diluent. Following the addition of diluent to the lyophilized powder, each vial should be repeatedly inverted or rocked, not shaken, for at least 30 seconds prior to infusion.
</p>
<p>Hydroxocobalamin solutions should be visually inspected for particulate matter and color prior to administration. If the reconstituted solution is not dark red or if particulate matter is seen after the solution has been appropriately mixed, the solution should be discarded.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Incompatibility Information
</h2>
<p class="First">Physical incompatibility (particle formation) and chemical incompatibility were observed with the mixture of hydroxocobalamin in solution with selected drugs that are frequently used in resuscitation efforts. Hydroxocobalamin is also chemically incompatible with sodium thiosulfate and sodium nitrite and has been reported to be incompatible with ascorbic acid.  Therefore, these and other drugs should not be administered simultaneously through the same intravenous line as hydroxocobalamin.
</p>
<p>Simultaneous administration of hydroxocobalamin and blood products (whole blood, packed red cells, platelet concentrate and/or fresh frozen plasma) through the same intravenous line is not recommended.  However, blood products and hydroxocobalamin can be administered simultaneously using separate intravenous lines (preferably on contralateral extremities, if peripheral lines are being used).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Storage of Reconstituted Drug Product
</h2>
<p class="First">Once reconstituted, hydroxocobalamin is stable for up to 6 hours at temperatures not exceeding 40Â°C (104Â°F). Do not freeze. Any reconstituted product not used by 6 hours should be discarded.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s9"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Cyanokit (hydroxocobalamin for injection) 5Â g for intravenous infusion consists of 2 vials, each containing 2.5Â g lyophilized hydroxocobalamin dark red crystalline powder for injection.  After reconstitution, each vial contains hydroxocobalamin for injection, 25Â mg/mL.  Administration of both vials constitutes a single dose [<span class="Italics">see How Supplied/Storage and Handling (<a href="#s47">16</a>)</span> for full kit description].
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">None
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s11"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Emergency Patient Management
</h2>
<p class="First">In addition to Cyanokit, treatment of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> must include immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity. Consideration should be given to decontamination measures based on the route of exposure.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span>
</h2>
<p class="First">Use caution in the management of patients with known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to hydroxocobalamin or cyanocobalamin. Consideration should be given to use of alternative therapies, if available.
</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may include: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span> have also been reported in postmarketing experience.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Blood Pressure Increase
</h2>
<p class="First">Many patients with cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> will be hypotensive; however, elevations in blood pressure have also been observed in known or suspected cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> victims.
</p>
<p>Elevations in blood pressure (â‰¥ 180 mmHg systolic or â‰¥ 110 mmHg diastolic) were observed in approximately 18% of healthy subjects (not exposed to cyanide) receiving hydroxocobalamin 5 g and 28% of subjects receiving 10 g. Increases in blood pressure were noted shortly after the infusions were started; the maximal increase in blood pressure was observed toward the end of the infusion. These elevations were generally transient and returned to baseline levels within 4 hours of dosing.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use of Blood Cyanide Assay
</h2>
<p class="First">While determination of blood cyanide concentration is not required for management of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and should not delay treatment with Cyanokit, collecting a pretreatment blood sample may be useful for documenting cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> as sampling post-Cyanokit use may be inaccurate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Interference with Clinical Laboratory Evaluations and Clinical Methods
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-5.5.1"></a><p></p>
<p class="First"><span class="Underline">
Clinical Laboratory Evaluations
</span></p>
<p>Because of its deep red color, hydroxocobalamin has been found to interfere with colorimetric determination of certain laboratory parameters (e.g., clinical chemistry, hematology, coagulation, and urine parameters). <span class="Italics">In-vitro</span> tests indicated that the extent and duration of the interference are dependent on numerous factors such as the dose of hydroxocobalamin, analyte, methodology, analyzer, hydroxocobalamin concentration, and partially on the time between sampling and measurement.
</p>
<p>Based on in-vitro studies and pharmacokinetic data obtained in healthy volunteers, the following table (<a href="#t2">Table 2</a>) describes laboratory interference that may be observed following a 5 g dose of hydroxocobalamin. Interference following a 10 g dose can be expected to last up to an additional 24 hours. The extent and duration of interference in cyanide-poisoned patients may differ. Results may vary substantially from one analyzer to another; therefore, caution should be used when reporting and interpreting laboratory results.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2 Laboratory Interference Observed with In-Vitro Samples of Hydroxocobalamin
</span></caption>
<col align="left" width="16.336%">
<col align="left" width="17.903%">
<col align="left" width="17.820%">
<col align="left" width="15.836%">
<col align="left" width="15.919%">
<col align="left" width="16.186%">
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" align="center" valign="top">Laboratory
</th>
<th class="Rrule Toprule" align="center" valign="top">No Interference
</th>
<th class="Rrule Toprule" align="center" valign="top">Artificially
</th>
<th class="Rrule Toprule" align="center" valign="top">Artificially
</th>
<th class="Rrule Toprule" align="center" valign="top">Un-predictable
</th>
<th class="Rrule Toprule" align="center" valign="top">Duration of
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center" valign="top">Parameter
</th>
<th class="Botrule Rrule" align="center" valign="top">Observed
</th>
<th class="Botrule Rrule" align="center" valign="top">Increased *
</th>
<th class="Botrule Rrule" align="center" valign="top">Decreased *
</th>
<th class="Botrule Rrule" align="center" valign="top"></th>
<th class="Botrule Rrule" align="center" valign="top">Interference
</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="6" valign="top"><p class="First Footnote">* â‰¥10% interference observed on at least 1 analyzer
</p></td></tr>
<tr class="Last"><td align="left" colspan="6" valign="top"><p class="First Footnote">Analyzers used: ACL Futura (Instrumentation Laboratory), AxSYM<span class="Sup">Â®</span>/Architect<span class="Sup">TM</span> (Abbott), BM Coasys<span class="Sup">110</span> (Boehringer Mannheim), CellDyn 3700<span class="Sup">Â®</span> (Abbott), Clinitek<span class="Sup">Â®</span> 500 (Bayer), Cobas Integra<span class="Sup">Â®</span> 700, 400 (Roche), Gen-S Coultronics, Hitachi 917, STA<span class="Sup">Â®</span> Compact, Vitros<span class="Sup">Â®</span> 950 (Ortho Diagnostics)
</p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Clinical</span></td>
<td class="Rrule" align="left" valign="top">Calcium
</td>
<td class="Rrule" align="left" valign="top">Creatinine
</td>
<td class="Rrule" align="left" valign="top">ALT
</td>
<td class="Rrule" align="left" valign="top">Phosphate
</td>
<td class="Botrule Rrule" align="left" rowspan="6" valign="top">24 hours with the exception of bilirubin (up to 4 days)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Chemistry</span></td>
<td class="Rrule" align="left" valign="top">Sodium
</td>
<td class="Rrule" align="left" valign="top">Bilirubin
</td>
<td class="Rrule" align="left" valign="top">Amylase
</td>
<td class="Rrule" align="left" valign="top">Uric Acid
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">Potassium
</td>
<td class="Rrule" align="left" valign="top">Triglycerides
</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">AST
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">Chloride
</td>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>
</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">CK
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">Urea
</td>
<td class="Rrule" align="left" valign="top">Total protein
</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">CKMB
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">GGT
</td>
<td class="Botrule Rrule" align="left" valign="top">GlucoseÂ <br>AlbuminÂ <br>AlkalineÂ <br>phosphatase
</td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">LDH
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Hematology</span></td>
<td class="Botrule Rrule" align="left" valign="top">erythrocytes<br>Hematocrit<br>MCV<br>Leukocytes<br><span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">Lymphocytes</span><br>Monocytes<br>Eosinophils<br><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span><br>Platelets
</td>
<td class="Botrule Rrule" align="left" valign="top">Hemoglobin<br>MCH<br>MCHC<br><span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">Basophils</span>
</td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">12 - 16 hours
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Coagulation</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">aPTT<br>PT (Quick or INR)
</td>
<td class="Botrule Rrule" align="left" valign="top">24 - 48 hours
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Urinalysis</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">pH (with all doses)
</td>
<td class="Botrule Rrule" align="left" rowspan="3" valign="top">pH (with equivalent doses of &lt;5 g)
</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" rowspan="3" valign="top">48 hours up to 8 days; color changes may persist up to 28 days
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">Glucose
</td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Protein<br>Erythrocytes<br>Leukocytes<br><span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">Ketones</span><br>Bilirubin<br>Urobilinogen<br>Nitrite
</td>
<td class="Botrule Rrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-5.5.2"></a><p></p>
<p class="First"><span class="Underline">
Clinical Methods
</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>
 Because of its deep red color, hydroxocobalamin may cause hemodialysis machines to shut down due to an erroneous detection of a â€œblood leakâ€?.  This should be considered before hemodialysis is initiated in patients treated with hydroxocobalamin.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity</span>
</h2>
<p class="First">Hydroxocobalamin absorbs visible light in the UV spectrum. It therefore has potential to cause <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>. While it is not known if the skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> predisposes to <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, patients should be advised to avoid direct sun while their skin remains discolored.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s18"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">Serious adverse reactions with hydroxocobalamin include <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and increases in blood pressure <span class="Italics">[see Warnings and Precautions (<a href="#s13">5.2</a>, <a href="#s14">5.3</a>)].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical trials were conducted under widely varying conditions, adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Experience in Healthy Subjects</span></p>
<p>A double-blind, randomized, placebo-controlled, single-ascending-dose (2.5, 5, 7.5, and 10 g) study was conducted to assess the safety, tolerability, and pharmacokinetics of hydroxocobalamin in 136 healthy adult subjects. Because of the dark red color of hydroxocobalamin, the two most frequently occurring adverse reactions were <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">chromaturia</span> (red-colored urine) which was reported in all subjects receiving a 5 g dose or greater; and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>), which occurred in most subjects receiving a 5 g dose or greater. Adverse reactions reported in at least 5% of the 5 g dose group and corresponding rates in the 10 g and placebo groups are shown in <a href="#t3">Table 3</a>.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3 Incidence of Adverse Reactions Occurring in &gt;5% of Subjects in 5 g Dose Group and Corresponding Incidence in 10 g Dose Group and Placebo
</span></caption>
<col align="left" width="27.914%">
<col align="left" width="21.536%">
<col align="left" width="14.417%">
<col align="left" width="22.935%">
<col align="left" width="13.197%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">* <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> were predominantly acneiform
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">5 g Dose Group</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">10 g Dose Group</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<br><br><br><span class="Bold">ADR</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><span class="Bold">Hydroxocobalamin
</span><br><span class="Bold">N=66
</span><br><span class="Bold">n (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><span class="Bold">Placebo
</span><br><span class="Bold">N=22
</span><br><span class="Bold">n (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><span class="Bold">Hydroxocobalamin
</span><br><span class="Bold">N=18
</span><br><span class="Bold">n (%)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br><span class="Bold">Placebo N=6
</span><br><span class="Bold">n (%)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">Chromaturia</span> (red colored urine)
</td>
<td class="Botrule Rrule" align="center" valign="top">66 (100)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">18 (100)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">62 (94)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">18 (100)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>*
</td>
<td class="Botrule Rrule" align="center" valign="top">13 (20)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">8 (44)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">Blood pressure increased</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">12 (18)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">5 (28)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (6)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (5)
</td>
<td class="Botrule Rrule" align="center" valign="top">2 (11)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (6)
</td>
<td class="Botrule Rrule" align="center" valign="top">1 (5)
</td>
<td class="Botrule Rrule" align="center" valign="top">6 (33)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Lymphocyte percent decreased
</td>
<td class="Botrule Rrule" align="center" valign="top">5 (8)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (17)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Infusion site reaction
</td>
<td class="Botrule Rrule" align="center" valign="top">4 (6)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
<td class="Botrule Rrule" align="center" valign="top">7 (39)
</td>
<td class="Botrule Rrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
<p>In this study, the following adverse reactions were reported to have occurred in a dose-dependent fashion and with greater frequency than observed in placebo-treated cohorts: <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span> (particularly diastolic blood pressure), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and infusion site reactions. All were mild to moderate in severity and resolved spontaneously when the infusion was terminated or with standard supportive therapies.
</p>
<p>Other adverse reactions reported in this study and considered clinically relevant were:
</p>
<ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, irritation, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>
</li>
<li>
<span class="Italics">General disorders and administration site conditions:</span> <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
</li>
<li>
<span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>
</li>
<li>
<span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>, <span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">dry throat</span>
</li>
<li>
<span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Experience in Known or Suspected Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> Victims</span></p>
<p>Four open-label, uncontrolled, clinical studies (one of which was prospective and three of which were retrospective) were conducted in known or suspected cyanide-<span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> victims. A total of 245 patients received hydroxocobalamin treatment in these studies. Systematic collection of adverse events was not done in all of these studies and interpretation of causality is limited due to the lack of a control group and due to circumstances of administration (e.g., use in fire victims). Adverse reactions reported in these studies listed by system organ class included:
</p>
<ul class="Disc">
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">ventricular extrasystoles</span>
</li>
<li>
<span class="Italics">Investigations:</span> electrocardiogram repolarization abnormality, <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>
</li>
<li>
<span class="Italics">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>
</li>
</ul>
<p>Adverse reactions common to both the studies in known or suspected cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> victims and the study in healthy volunteers are listed in the healthy volunteer section only and are not duplicated in this list.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s22"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First">No formal drug interaction studies have been conducted with Cyanokit.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s23"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s24"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<p class="First">Pregnancy Category C.  There are no adequate and well controlled studies of Cyanokit in pregnant women. In animal studies, hydroxocobalamin caused skeletal and visceral (soft tissue) abnormalities at exposures (based on AUC) similar to human exposures at the therapeutic dose. Cyanokit should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because cyanide readily crosses the placenta, maternal cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> results in fetal cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. Timely treatment of the pregnant mother may be lifesaving for both mother and fetus.
</p>
<p>In animal studies, pregnant rats and rabbits received Cyanokit (75, 150, or 300 mg/kg/d) during the period of  organogenesis. Following intraperitoneal dosing in rats and intravenous dosing in rabbits, maternal exposures were equivalent to 0.5, 1, or 2 times the human exposure at the therapeutic dose (based on AUC).  In the high dose groups for both species, maternal toxicity occurred, and there was a reduced number of live fetuses due to embryofetal resorptions.  In addition, decreased live fetal weight occurred in high dose rats, but not in rabbits. Incomplete skeletal ossification occurred in both rats and rabbits. In rats, two fetuses of the high dose group and two fetuses of the mid dose group (each from a different litter) had short, rudimentary or small front or hind legs. Rabbit litters and fetuses exhibited a dose dependant increase in various gross soft tissue and skeletal anomalies. The main findings in rabbits were flexed, rigid flexor or medially rotated forelimbs or hindlimbs and domed heads at external examination; enlarged anterior or posterior fontanelles of the ventricles of the brain and flat, bowed or large ribs at skeletal examination; and dilated ventricles of the brain, and thick wall of the stomach at visceral examination.
</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s25"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery
</h2>
<p class="First">The effect of Cyanokit on labor and delivery is unknown.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s26"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether hydroxocobalamin is excreted in human milk.  Cyanokit may be administered in life-threatening situations, and therefore, breastfeeding is not a contraindication to its use.  Because of the unknown potential for adverse reactions in nursing infants, the patient should discontinue nursing after receiving Cyanokit.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s27"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness of Cyanokit have not been established in this population. In non-US marketing experience, a dose of 70 mg/kg has been used to treat pediatric patients.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s28"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Approximately 50 known or suspected cyanide victims aged 65 or older received hydroxocobalamin in clinical studies. In general, the safety and effectiveness of hydroxocobalamin in these patients was similar to that of younger patients. No adjustment of dose is required in elderly patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">The safety and effectiveness of Cyanokit have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
</p>
<p>Hydroxocobalamin and cyanocobalamin are eliminated unchanged by the kidneys. Oxalate crystals have been observed in the urine of both healthy subjects given hydroxocobalamin and patients treated with hydroxocobalamin following suspected cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">The safety and effectiveness of Cyanokit have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s31"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">No data are available about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Cyanokit in adults.  Should <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occur, treatment should be directed to the management of symptoms.  Hemodialysis may be effective in such a circumstance, but is only indicated in the event of significant hydroxocobalamin-related toxicity.  Because of its deep red color, hydroxocobalamin may interfere with the performance of hemodialysis machines  
<span class="Italics">
[see Warnings and Precautions (<a href="#s16">5.5</a>)].
</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s32"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">Hydroxocobalamin, the active ingredient in Cyanokit, is cobinamide dihydroxide dihydrogen phosphate (ester), mono (inner salt), 3'-ester with 5,6-dimethyl-1-Î±-D-ribofuranosyl-1H-benzimidazole.  The drug substance is the hydroxylated active form of vitamin B<span class="Sub">12</span> and is a large molecule in which a trivalent cobalt ion is coordinated in four positions by a tetrapyrol (or corrin) ring.  It is a hygroscopic, odorless, dark red, crystalline powder that is freely soluble in water and ethanol, and practically insoluble in acetone and diethyl ether. Hydroxocobalamin has a molecular weight of 1346.36 atomic <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> units, an empirical formula of C<span class="Sub">62</span>H<span class="Sub">89</span>CoN<span class="Sub">13</span>O<span class="Sub">15</span>P and the following structural formula: 
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=416c7978-5661-6e63-6546-6f7265766572&amp;name=cya00-0006-01.jpg">
</div>
<p> Cyanokit (hydroxocobalamin for injection) 5Â g for intravenous infusion is a cyanide antidote package which contains two colorless 250Â mL glass vials, each of which contains 2.5Â g dark red lyophilized hydroxocobalamin, pH adjusted with hydrochloric acid, two transfer spikes, one intravenous administration set, one quick use reference guide and one package insert.
</p>
<p> Each 2.5Â g vial of hydroxocobalamin for injection is to be reconstituted with 100Â mL of 0.9% NaCl, to give a dark red injectable solution (25Â mg/mL).  If 0.9% NaCl is not readily available, 100Â mL of either Lactated Ringers injection or 5% Dextrose injection (D5W) may be used as the diluent.  Diluent is not included in the Cyanokit.  The pH of the reconstituted product ranges from 3.5 to 6.0.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s33"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s34"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> and <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>. In massive acute cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, the mechanism of toxicity may involve other enzyme systems as well. Signs and symptoms of acute systemic cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may develop rapidly within minutes, depending on the route and extent of cyanide exposure.
</p>
<p>The action of Cyanokit in the treatment of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is based on its ability to bind cyanide ions. Each hydroxocobalamin molecule can bind one cyanide ion by substituting it for the hydroxo ligand linked to the trivalent cobalt ion, to form cyanocobalamin, which is then excreted in the urine.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s35"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<p class="First">Administration of Cyanokit to cyanide-poisoned patients with the attendant formation of cyanocobalamin resulted in increases in blood pressure and variable changes in heart rate upon initiation of hydroxocobalamin infusions.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s36"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">Following intravenous administration of hydroxocobalamin significant binding to plasma proteins and low molecular weight physiological compounds occurs, forming various cobalamin-(III) complexes by replacing the hydroxo ligand. The low molecular weight cobalamins-(III) formed, including hydroxocobalamin, are termed â€œfree cobalamins-(III)â€?; the sum of free and protein-bound cobalamins is termed â€œtotal cobalamins-(III)â€?. In order to reflect the exposure to the sum of all derivatives, pharmacokinetics of cobalamins-(III) (i.e. cobalamin-(III) entity without specific ligand) were investigated instead of hydroxocobalamin alone, using the concentration unit Î¼g eq/mL.
</p>
<p> Dose-proportional pharmacokinetics were observed following single dose intravenous administration of 2.5 to 10Â g of hydroxocobalamin in healthy volunteers.  Mean free and total cobalamins-(III) C<span class="Sub">max</span> values of 113 and 579Â Î¼gÂ eq/mL, respectively, were determined following a dose of 5Â g of hydroxocobalamin.  Similarly, mean free and total cobalamins-(III) C<span class="Sub">max</span> values of 197 and 995Â Î¼gÂ eq/mL, respectively, were determined following the dose of 10Â g of hydroxocobalamin.  The predominant mean half-life of free and total cobalamins-(III) was found to be approximately 26 to 31 hours at both the 5Â g and 10Â g dose level.
</p>
<p> The mean total amount of cobalamins-(III) excreted in urine during the collection period of 72 hours was about 60% of a 5Â g dose and about 50% of a 10Â g dose of hydroxocobalamin.  Overall, the total urinary excretion was calculated to be at least 60 to 70% of the administered dose.  The majority of the urinary excretion occurred during the first 24Â hours, but red-colored urine was observed for up to 35 days following the intravenous infusion.
</p>
<p> When normalized for body weight, male and female subjects revealed no major differences in pharmacokinetic parameters of free and total cobalamins-(III) following the administration of 5 and 10Â g of hydroxocobalamin.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s37"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s38"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential of hydroxocobalamin. Hydroxocobalamin was negative in the following mutagenicity assays: <span class="Italics">in vitro</span> bacterial reverse mutation assay using <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> and <span class="Italics">Escherichia coli</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, an <span class="Italics">in-vitro</span> assay of the tk locus in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, and an <span class="Italics">in-vivo</span> rat micronucleus assay.
</p>
<p>The effect of hydroxocobalamin on fertility has not been evaluated.
</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="s39"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Pharmacology
</h2>
<p class="First"> Evidence of the effectiveness of hydroxocobalamin for treatment of cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> was obtained primarily from studies in animals due to the ethical considerations of performing such controlled studies in humans. While the results of these animal studies cannot be extrapolated to humans with certainty, the extrapolation is supported by the understanding of the pathophysiologic mechanisms of the toxicity of cyanide and the mechanisms of the protective effect of hydroxocobalamin as examined in dogs. In addition, the results of uncontrolled human studies and the animal study establish that hydroxocobalamin is likely to produce clinical benefit in humans.
</p>
<p> The effectiveness of hydroxocobalamin was examined in a randomized, placebo-controlled, blinded study in cyanide-poisoned adult dogs assigned to treatment with vehicle (0.9% saline), or 75Â orÂ 150Â mg/kg hydroxocobalamin.   Anesthetized dogs were poisoned by intravenous administration of a lethal dose of potassium cyanide.  Dogs then received vehicle or 75Â orÂ 150Â mg/kg hydroxocobalamin, administered intravenously over 7.5 minutes.  The 75 and 150Â mg/kg doses are approximately equivalent to 5 and 10Â g of hydroxocobalamin (respectively) in humans based on both body weight and the C<span class="Sub">max</span> of hydroxocobalamin (total cobalamins-(III)).  Survival at 4 hours and at 14 days was significantly greater in low-and high-dose groups compared with dogs receiving vehicle alone (<a href="#t4">Table 4</a>).  Hydroxocobalamin reduced whole blood cyanide concentrations by approximately 50% by the end of the infusion compared with vehicle.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4 Survival of Cyanide-Poisoned Dogs
</span></caption>
<col align="left" width="38.875%">
<col align="left" width="20.675%">
<col align="left" width="21.825%">
<col align="left" width="18.625%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="middle">
<br><br><span class="Bold">Parameter</span>
</th>
<th class="Botrule Rrule Toprule" align="center" colspan="3" valign="top"><span class="Bold">Treatment</span></th>
</tr>
<tr>
<th class="Botrule Rrule" align="center" rowspan="2" valign="top">
<br><span class="Bold">Vehicle
</span><br><span class="Bold">N=17</span>
</th>
<th class="Botrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">Cyanokit</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">75 mg/kg
</span><br><span class="Bold">N=19</span>
</th>
<th class="Botrule Rrule" align="center" valign="top">
<span class="Bold">150 mg/kg
</span><br><span class="Bold">N=18</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">Survival at Hour 4, n (%)
</td>
<td class="Botrule Rrule" align="center" valign="top">7 (41)
</td>
<td class="Botrule Rrule" align="center" valign="top">18 (95)
</td>
<td class="Botrule Rrule" align="center" valign="top">18 (100)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Survival at Day 14, n (%)
</td>
<td class="Botrule Rrule" align="center" valign="top">3 (18)
</td>
<td class="Botrule Rrule" align="center" valign="top">15 (79)
</td>
<td class="Botrule Rrule" align="center" valign="top">18 (100)
</td>
</tr>
</tbody>
</table>
<p> Histopathology revealed brain lesions that were consistent with cyanide-induced <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>.  The incidence of brain lesions was markedly lower in hydroxocobalamin treated animals compared to vehicle treated groups.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s40"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">Due to ethical considerations, no controlled human efficacy studies have been performed. A controlled animal study demonstrated efficacy in cyanide-poisoned adult dogs <span class="Italics">[see Animal Pharmacology (<a href="#s39">13.2</a>)].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Smoke Inhalation Victims
</h2>
<p class="First">A prospective, uncontrolled, -open-label study was carried out in 69 subjects who had been exposed to smoke inhalation from fires.  Subjects had to be over 15 years of age, present with soot in the mouth and expectoration (to indicate significant smoke exposure), and have altered neurological status.  The median hydroxocobalamin dose was 5Â g with a range from 4 to 15Â g.</p>
<p>Fifty of 69 subjects (73%) survived following treatment with hydroxocobalamin.  Nineteen subjects treated with hydroxocobalamin did not survive.  Fifteen patients treated with hydroxocobalamin were in <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> initially at the scene; 13 of these subjects died and 2 survived.
</p>
<p> Of the 42 subjects with pretreatment cyanide levels considered to be potentially toxic, 28Â (67%) survived.  Of the 19 subjects whose pretreatment cyanide levels were considered potentially lethal, 11 (58%) survived.  Of the 50 subjects who survived, 9 subjects (18%) had neurological sequelae at hospital discharge.  These included <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>, <span class="product-label-link" type="condition" conceptid="4229448" conceptname="Anterograde amnesia">anterograde amnesia</span>, intellectual deterioration moderate <span class="product-label-link" type="condition" conceptid="4046815" conceptname="Dysdiadochokinesis">cerebellar syndrome</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, and <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>.
</p>
<p>Two additional retrospective, uncontrolled studies were carried out in subjects who had been exposed to cyanide from fire or smoke inhalation.  Subjects were treated with up to 15Â g of hydroxocobalamin.  Survival in these two studies was 34 of 61 (56%) for one study, and 30 of 72 (42%) for the second.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> by Ingestion or Inhalation
</h2>
<p class="First">A retrospective, uncontrolled study was carried out in 14 subjects who had been exposed to cyanide from sources other than from fire or smoke (i.e., ingestion or inhalation). Subjects were treated with 5 to 20 g of hydroxocobalamin. Eleven of 12 subjects whose blood cyanide concentration was known had initial blood cyanide levels considered to be above the lethal threshold.
</p>
<p>Ten of 14 subjects (71%) survived, following administration of hydroxocobalamin. One of the four subjects who died had presented in <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. Of the 10 subjects who survived, only 1 subject had neurological sequelae at hospital discharge. This subject had post-<span class="product-label-link" type="condition" conceptid="377845" conceptname="Anoxic encephalopathy">anoxic encephalopathy</span>, with <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, considered to be due to cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Cross-Study Findings
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-13.3.1"></a><p></p>
<p class="First"><span class="Underline">Experience with Dosing Greater than 10 g of Hydroxocobalamin</span></p>
<p>Across all four uncontrolled studies, 10 patients who did not demonstrate a full response to 5 or 10 g-doses of hydroxocobalamin were treated with more than 10 g of hydroxocobalamin. One of these 10 patients survived with unspecified neurological sequelae.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-13.3.2"></a><p></p>
<p class="First"><span class="Underline">Effects on Blood Pressure</span></p>
<p>Initiation of hydroxocobalamin infusion as part of the therapeutic interventions generally resulted in increases in blood pressure and variable changes in heart rate (often normalization).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-13.3.3"></a><p></p>
<p class="First"><span class="Underline">Survival of Patients Presenting in <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac Arrest</span></span></p>
<p>Of the 245 patients across all four studies, 68 (28%) presented in <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>. While blood pressure and heart rate may have been restored in many of these 68 patients, only five (7%) survived.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s47"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Each Cyanokit carton (NDC 11704-270-01) consists of the following:
</p>
<ul class="Disc">
<li>Two 250Â mL glass vials, each containing lyophilized hydroxocobalamin for injection, 2.5Â g
</li>
<li>Two sterile transfer spikes
</li>
<li>One sterile intravenous infusion set
</li>
<li>One quick use reference guide
</li>
<li>One package insert
</li>
</ul>
<p>Diluent is not included
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s48"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-14.2"></a><p></p>
<p class="First"><span class="Bold">Lyophilized form:</span> Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59 to 86Â°F) [<span class="Italics">see USP Controlled Room Temperature</span>].
</p>
<p>Cyanokit may be exposed during short periods to the temperature variations of usual transport (15 days submitted to temperatures ranging from 5 to 40Â°C (41 to 104Â°F), transport in the desert (4 days submitted to temperatures ranging from 5 to 60Â°C (41 to 140Â°F)) and freezing/defrosting cycles (15 days submitted to temperatures ranging from -20 to 40Â°C (-4 to 104Â°F)).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-14.3"></a><p></p>
<p class="First"><span class="Bold">Reconstituted solution:</span> Store up to 6 hours at a temperature not exceeding 40ÂºC (104Â°F). Do not freeze. Discard any unused portion after 6 hours.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s51"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">Cyanokit is indicated for cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and in this setting, patients will likely be unresponsive or may have difficulty in comprehending counseling information.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-15.1"></a><p></p>
<h2>17.1 <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> and <span class="product-label-link" type="condition" conceptid="4055281" conceptname="Urine color abnormal">Chromaturia</span>
</h2>
<p class="First">Patients should be advised that skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> may last up to 2 weeks and urine coloration may last for up to 5 weeks after administration of Cyanokit. While it is not known if the skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> predisposes to <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, patients should be advised to avoid direct sun while their skin remains discolored.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-15.2"></a><p></p>
<h2>17.2 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</h2>
<p class="First">In some patients an acneiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may appear anywhere from 7 to 28 days following hydroxocobalamin treatment. This <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> will usually resolve without treatment within a few weeks.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Pregnancy and Breastfeeding
</h2>
<p class="First">Patients should be advised that maternal cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> results in fetal cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. Treatment for cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may be lifesaving for both mother and fetus. Patients should notify their physician if they were pregnant during therapy with Cyanokit [see <span class="Italics">Use In Specific Populations (<a href="#s24">8.1</a></span>)]. It is not known whether hydroxocobalamin is excreted in human milk.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-15.4"></a><p></p>
<h2>17.4 FDA-Approved Patient Labeling
</h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s56"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">Cyanokit (hydroxocobalamin for injection) 5Â g for intravenous infusion</span></p>
<p><span class="Bold">Treatment for known or suspected cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span></span></p>
<p><span class="Bold">What is Cyanokit?</span></p>
<p>Cyanokit is an emergency treatment (antidote) used in patients with known or suspected cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>.  Cyanide is a chemical poison.  Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> can happen from:
</p>
<ul class="Disc">
<li>breathing smoke from household and industrial fires
</li>
<li>breathing or swallowing cyanide
</li>
<li>having your skin exposed to cyanide
</li>
</ul>
<p>Cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is a life-threatening condition because cyanide stops your body from being able to use oxygen.  You can die if your body does not have enough oxygen.
</p>
<p>Cyanokit was approved for the treatment of known or suspected cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> based on testing:
</p>
<ul class="Disc">
<li>how well it worked in animals (It is not ethical to poison people with cyanide in order to test a treatment.)
</li>
<li>its safety in people with cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>
</li>
</ul>
<p><span class="Bold">How is Cyanokit used?</span></p>
<p>Cyanokit is given through a vein (intravenous) over 15 minutes by an emergency care provider or doctor.  A second dose may be given to you if needed.
</p>
<p><span class="Bold">What are possible side effects with Cyanokit?</span></p>
<p><span class="Bold">Serious side effects may include:</span></p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></span>  Signs of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> include <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span>, trouble breathing, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.
</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span></span></li>
</ul>
<p><span class="Bold">Other side effects may include:</span></p>
<ul class="Disc">
<li><span class="Bold">red colored urine</span></li>
<li><span class="Bold">red colored skin and mucous membranes, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>-like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>, trouble swallowing, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">throat tightness</span>, <span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">dry throat</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, memory problems, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></span></li>
<li><span class="Bold">infusion site reaction</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>, irritation, or <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span></span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="133299" conceptname="Swelling of limb">swelling of feet</span> and ankles</span></li>
<li><span class="Bold">irregular heart beat, increased heart rate</span></li>
<li><span class="Bold">fluid in lungs</span></li>
</ul>
<p>These are not all the side effects with Cyanokit.
</p>
<p><span class="Bold">After treatment with Cyanokit:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Skin and urine <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>.</span>  Skin <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> may last up to 2 weeks.  Avoid sun exposure while your skin is red.  Urine <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> may last up to 5 weeks.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>-like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</span>  An <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>-like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may appear 7 to 28 days after treatment with Cyanokit.  This <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> usually goes away without any treatment.
</li>
<li>
<span class="Bold">Pregnancy.</span>  Be sure to tell your doctor immediately if you were pregnant or think you may have been pregnant during treatment with Cyanokit. Treatment for cyanide <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> may save your life and the life of your unborn baby.
</li>
<li>
<span class="Bold">Breastfeeding.</span>  Talk to your doctor if you breastfeed your child. The ingredient in Cyanokit may pass into your breast milk.
</li>
</ul>
<p>Talk to your doctor about any side effect that bothers you or that does not go away.
</p>
<p>Manufactured by:<br>Merck SantÃ© s.a.s.,<br>Semoy, France
</p>
<p>Distributed by<br>Meridian Medical Technologiesâ„¢, Inc.<br>Columbia, MD 21046<br>A wholly-owned subsidiary of King Pharmaceuticals<span class="Sup">Â®</span>, Inc.<br>1-800-776-3637
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s57"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g BOTTLE LABEL</span></p>
<p><span class="Bold Italics">Cyanokit
</span><span class="Sup">Â®
</span><span class="Bold Italics">5 g</span></p>
<p><span class="Bold">Hydroxocobalamin for Injection</span></p>
<p><span class="Bold">(2.5 g per vial)</span></p>
<p>For Intravenous Use
</p>
<p>To be reconstituted with 100 mL
</p>
<p>per vial of 0.9% Sodium Chloride Injection
</p>
<p><span class="Bold">Diluent Not Included</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Manufactured by:
</p>
<p>Merck SantÃ© s.a.s.,
</p>
<p>Semoy, France
</p>
<p>Distributed by
</p>
<p>Meridian Medical Technologies<span class="Sup">TM</span>, Inc.
</p>
<p>Columbia, MD 21046
</p>
<p>A wholly-owned subsidiary of King Pharmaceuticals<span class="Sup">Â®</span>, Inc.
</p>
<p>1-800-776-3637
</p>
<p><span class="Bold">MERIDIAN</span></p>
<p><span class="Bold">MEDICAL TECHNOLOGIESâ„¢</span></p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g BOTTLE LABEL
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=416c7978-5661-6e63-6546-6f7265766572&amp;name=cya00-0006-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s58"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g INNER CARTON</span></p>
<p><span class="Bold Italics">Cyanokit
</span><span class="Sup">Â®
</span><span class="Bold Italics">5 g</span></p>
<p><span class="Bold">Hydroxocobalamin for Injection</span></p>
<p><span class="Bold">(2.5 g per vial)</span></p>
<p>For Intravenous Use
</p>
<p>To be reconstituted with 100 mL
</p>
<p>per vial of 0.9% Sodium Chloride Injection
</p>
<p><span class="Bold">Diluent Not Included</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Manufactured by:
</p>
<p>Merck SantÃ© s.a.s.,
</p>
<p>Semoy, France
</p>
<p>Distributed by
</p>
<p>Meridian Medical Technologies<span class="Sup">TM</span>, Inc.
</p>
<p>Columbia, MD 21046
</p>
<p>A wholly-owned subsidiary of King Pharmaceuticals<span class="Sup">Â®</span>, Inc.
</p>
<p>1-800-776-3637
</p>
<p><span class="Bold">MERIDIAN</span></p>
<p><span class="Bold">MEDICAL TECHNOLOGIESâ„¢</span></p>
<div class="Figure">
<a name="f03"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g INNER CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=416c7978-5661-6e63-6546-6f7265766572&amp;name=cya00-0006-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s59"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g OUTER CARTON</span></p>
<p><span class="Bold Italics">Cyanokit
</span><span class="Sup">Â®
</span><span class="Bold Italics">5 g</span></p>
<p><span class="Bold">Hydroxocobalamin for Injection</span></p>
<p><span class="Bold">(2.5 g per vial)</span></p>
<p>For Intravenous Use
</p>
<p>To be reconstituted with 100 mL
</p>
<p>per vial of 0.9% Sodium Chloride Injection
</p>
<p><span class="Bold">Diluent Not Included</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>Manufactured by:
</p>
<p>Merck SantÃ© s.a.s.,
</p>
<p>Semoy, France
</p>
<p>Distributed by
</p>
<p>Meridian Medical Technologies<span class="Sup">TM</span>, Inc.
</p>
<p>Columbia, MD 21046
</p>
<p>A wholly-owned subsidiary of King Pharmaceuticals<span class="Sup">Â®</span>, Inc.
</p>
<p>1-800-776-3637
</p>
<p><span class="Bold">MERIDIAN</span></p>
<p><span class="Bold">MEDICAL TECHNOLOGIESâ„¢</span></p>
<div class="Figure">
<a name="f04"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g OUTER CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=416c7978-5661-6e63-6546-6f7265766572&amp;name=cya00-0006-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s60"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g PATIENT INSTRUCTION CARD SIDE A</span></p>
<p><span class="Bold Italics">Cyanokit
</span><span class="Sup">Â®
</span><span class="Bold Italics">5 g</span></p>
<p><span class="Bold">Hydroxocobalamin for Injection</span></p>
<p><span class="Bold">(2.5 g per vial)</span></p>
<p>For Intravenous Use
</p>
<p>To be reconstituted with 100 mL
</p>
<p>per vial of 0.9% Sodium Chloride Injection
</p>
<p><span class="Bold">Diluent Not Included</span></p>
<div class="Figure">
<a name="f05"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g PATIENT INSTRUCTION CARD SIDE A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=416c7978-5661-6e63-6546-6f7265766572&amp;name=cya00-0006-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s61"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g PATIENT INSTRUCTION CARD SIDE B</span></p>
<div class="Figure">
<a name="f06"></a><img alt="PACKAGE LABEL â€“ PRINCIPAL DISPLAY PANEL â€“ 5 g PATIENT INSTRUCTION CARD SIDE A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=416c7978-5661-6e63-6546-6f7265766572&amp;name=cya00-0006-06.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYANOKIT
Â 		
					</strong><br><span class="contentTableReg">hydroxocobalamin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:11704-270</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydroxocobalamin
</strong> (hydroxocobalamin) </td>
<td class="formItem">hydroxocobalamin
</td>
<td class="formItem">2.5Â g Â inÂ 100Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:11704-270-01</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022041</td>
<td class="formItem">08/31/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Meridian Medical Technologies, Inc.
							(167671341)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Merck SantÃ© s.a.s (384668112)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck SantÃ© s.a.s</td>
<td class="formItem"></td>
<td class="formItem">384953134</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck S.A. de C.V.</td>
<td class="formItem"></td>
<td class="formItem">810006213</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d3ecf5b0-e14c-4e91-ac44-8e5991747132</div>
<div>Set id: 416c7978-5661-6e63-6546-6f7265766572</div>
<div>Version: 7</div>
<div>Effective Time: 20110419</div>
</div>
</div>Â <div class="DistributorName">Meridian Medical Technologies, Inc.</div></p>
</body></html>
